IRVINE, Calif.–(BUSINESS WIRE)–#RespiratoryCare–Nihon Kohden, a global leader in medical technology, today announced the introduction of the industry’s first ventilators to receive Authority to Operate (ATO) certification under the Department of Defense’s (DoD) Risk Management Framework (RMF) eMASS #3389. This rigorous cybersecurity certification ensures Nihon Kohden’s ventilators meet the highest standards for data protection and operational security in healthcare settings.
“Our ATO-certified ventilators represent a new standard in medical device security,” said Roy Sakai, President of Nihon Kohden America. “This certification shows our commitment to protecting patient data and supporting healthcare providers in today’s digital world.”
Benefits of ATO-certified ventilators
Nihon Kohden’s commitment to maintaining this certification ensures its ventilators remain at the forefront of cybersecurity protection.
For more information about Nihon Kohden’s ATO-certified ventilators, please visit us.nihonkohden.com.
About Nihon Kohden
Founded in Japan in 1951, Nihon Kohden is a leading manufacturer, developer, and distributor of medical electronic equipment, with subsidiaries in the U.S., Europe, Asia, and Latin America. The company’s products are now used in more than 120 countries, and it is the largest supplier of electroencephalography products worldwide. A pioneer in transformational healthcare technology, Nihon Kohden has envisioned, designed, and produced revolutionary devices, such as pulse oximeters, arrhythmia analysis, low- invasive blood volume monitoring, and wireless patient monitoring.
Contacts
Beth Abbott
Senior Manager – Marketing Brand & Omnichannel
beth_abbott@nihonkohden.com
Data to be presented in Clinical Trials in Progress Session on Monday, April 28, 2025CORAL…
More than 50% of men now face erectile dysfunction after the age of 40. In…
BEIJING, April 27, 2025 (GLOBE NEWSWIRE) -- On April 25, 2025, the 66th (Spring 2025)…
After six months of research on the ingredients and thousands of feedback from real consumers,…
Data Presented at the AUA Meeting Reflect Longest-Term Data among FIT InterventionsSOUTH SAN FRANCISCO, Calif.,…
- Robust 24-month complete response rate of 42.3% by K-M for cretostimogene monotherapy in BOND-003…